-
Fingolimod safety review launched
3 Feb 12 | 10.03 | EU
The unexplained death of a patient shortly after starting treatment with fingolimod has led the European Medicines Agency’s Committee for Medicinal Products for Human Use to launch a safety review
more > -
MHRA rebuts Lancet accusations of failure to ensure medical device safety
30 Jan 12 | 16.19 | EU
The Medicines and Healthcare products Regulatory Agency has hit out against Lancet editor Richard Horton...
more > -
Give colecalciferol products UK licence, urges Soni
27 Jan 12 | 11.17 | England EU Northern Ireland Scotland Wales
Two colecalciferol products that are imported from Germany in substantial quantities for the treatment of vitamin D...
more > -
Anaphylaxis after vaccination of children very rare
24 Jan 12 | 17.12 | England EU Northern Ireland Scotland Wales
Anaphylaxis remains an adverse event that occurs very rarely in children after immunisation, according to prospective surveillance...
more > -
Dementia falls risk linked with SSRI dose
24 Jan 12 | 16.48 | EU
Selective serotonin reuptake inhibitors are associated with a dose-dependent increase in falls risk among elderly people with dementia...
more > -
Clamp down on free trade to protect supply chain, urges RPS
24 Jan 12 | 15.30 | England EU Northern Ireland Scotland Wales
Free trade of medicines between EU states should be made illegal in order to protect the UK medicines supply chain...
more > -
SSRI use during pregnancy linked with neonatal pulmonary hypertension
23 Jan 12 | 16.40 | EU
Taking selective serotonin reuptake inhibitors during late pregnancy doubles the risk of persistent pulmonary hypertension in the newborn, researchers claim more >
-
Fingolimod safety review launched over heart concerns
23 Jan 12 | 16.35 | EU
Multiple sclerosis drug fingolimod (Gilenya; Novartis) is being subjected to a safety review, launched by the European Medicines Agency...
more > -
Evidence and data are all important, aren’t they?
6 Jan 12 | 12.49 | England EU International Northern Ireland Scotland Wales
THIS week, the BMJ has raised the temperature in pharmaceutical research circles by calling for all data to be released when research is published, ie, the good and the bad as well as the frankly boring
more > -
EMA to undertake four-year herbal medicines review
6 Jan 12 | 11.32 | EU
A four-year programme that is intended to ensure the safety of herbal medicines has been announced by the European Medicines Agency...
more >
